• A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis

  NCT02289703

  CompletedInterventionalPhase 1Updated Jan 24, 2017
• Dose-finding of Rivaroxaban in Hemodialysis

  NCT02047006

  CompletedInterventionalPhase 4Updated Jan 14, 2015
• Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease

  NCT03969953

  CompletedInterventionalPhase 3Updated Mar 23, 2026
• Real-world Dosing Patterns of Rivaroxaban in the United States

  NCT03242278

  CompletedObservationalUpdated Jun 28, 2023
• Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal Dysfunction

  NCT03359876

  CompletedObservationalUpdated Dec 11, 2019
• Study to Gather Information on the Kidney Function of Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem) Treated With Rivaroxaban or Vitamin K Antagonists

  NCT04297072

  CompletedObservationalUpdated Mar 3, 2021

ClinicalTrials.gov ID

NCT05410275

Lead Sponsor

University Hospital, ToursOTHER

Overall Status

Recruiting

Study Type

Interventional

Phase

Phase 3

Enrollment

10Estimated

Last Update Posted

Jun 18, 2026Actual

Start Date

Jan 8, 2025Actual

Primary Completion Date

Jan 30, 2027Estimated

Completion Date

Jan 30, 2027Estimated

Official Title

Chronic Anticoagulation in End-stage Renal Disease Patients: Pharmacokinetics and Pharmacodynamic of a Reduced Dose Regimen of Rivaroxaban

Brief Summary

Atrial fibrillation is the most frequent cardiac rhythm disorder and its prognosis is essentially marked by the risk of embolic events. Its treatment is based on long-term oral anticoagulant therapy according to the risk of embolic events assessed by risk scores such as the CHA2DS2-Vasc score, but this prescription is associated with a risk of hemorrhagic events that must be taken into consideration when deciding on the treatment for a given patient. There are two categories of validated oral anticoagulant treatments for the prevention of embolic events in atrial fibrillation: antivitamin K agents, which have long been the reference treatment but are restrictive and difficult to use because of a narrow therapeutic window, and direct oral anticoagulants, which are now the first-line treatment but have not been evaluated in phase II and III studies in patients with severe renal failure. End-stage renal disease (clearance <15 mL/min/1.73m2), particularly at the dialysis stage, is a risk factor for cardiovascular disease in its own right, and a significant number of patients develop atrial fibrillation. Given the co-morbidities associated with renal failure, in particular hypertension, patients with renal failure undergoing dialysis and suffering from atrial fibrillation are generally at a higher risk of embolism than patients without renal failure, but also at a higher risk of bleeding. Thus, if the indication for prescribing oral anticoagulant therapy is clear in this population, the associated bleeding complications are also more frequent and more serious in these patients who have regular vascular accesses in the context of hemodialysis. There is thus a real need for reliable therapeutic alternatives with a better benefit/risk ratio than antivitamins K.

Translated with www.DeepL.com/Translator (free version)

Detailed Description

Chronic dialysis patients are a special population because the constraints linked to their disease (3 dialyses per week) make them a captive population that nephrologists know perfectly well. If the identification of the subjects to be included does not pose any problem, it is more their adherence to the project which is likely to be more difficult because it implies additional constraints in these patients with potentially many comorbidities.

This proof-of-concept study will identify the dose of rivaroxaban with the best pharmacokinetic/ pharmacodynamic profile in chronic hemodialysis patients. It will then be possible to envisage a larger study of the type of a national Hospital Clinical Research Program (PHRC) in order to evaluate the dose of rivaroxaban chosen in hemodialysis patients with atrial fibrillation with an indication for oral anticoagulation on the basis of morbidity-mortality criteria in comparison with treatment with antivitamins K that is well conducted.

• Chronic Hemodialysis Patients

• Rivaroxaban

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Adult patient ≥ 18 years of age,
• Chronic hemodialysis patient for at least 3 months,
• Affiliated or beneficiary of a social security plan,
• Having signed a written and informed consent.

Exclusion Criteria:

• Any indication for long-term oral anticoagulation (atrial fibrillation, venous thromboembolic disease, mechanical valve prostheses, intracardiac thrombosis, etc.)
• Double anti-platelet aggregation for any reason or an aspirin dose greater than 160 mg/day
• Uncontrolled hypertension (BP > 180/110 mmHg)
• Ischemic stroke within 30 days prior to inclusion
• History of major unprovoked hemorrhage (leading to hospitalization or transfusion) regardless of age
• Surgery within 30 days prior to inclusion
• High-risk bleeding condition in addition to renal failure (such as known coagulation disorder, thrombocytopenia (< 100G/L), active neoplasia of the digestive or urinary tract, or presence of intracranial vascular malformation)
• Severe hepatic impairment
• Use of strong CYP3A4 inducers, including rifampin, St. John's Wort, carbamazepine, phenytoin, phenobarbital
• Non-compliant patients
• Pregnant or breastfeeding women, women of childbearing age without effective contraception
• Contraindication to the administration of an anticoagulant treatment such as anti-phospholipid antibody syndrome
• Known allergy to rivaroxaban or to one of its excipients (lactose monohydrate)
• Patients under guardianship or conservatorship
• Patients already participating in an ongoing study or who have participated in a study that ended less than 30 days prior to the inclusion date.

Primary Purpose

Treatment

Allocation

N/A

Interventional Model

Single Group Assignment

Masking

None (Open Label)

Lead Sponsor

University Hospital, ToursOTHER

jf.valentin@chu-tours.fr02 47 47 37 78